Eculizumab
Brand Names: Soliris
Methodology & AI Transparency ⓘ
Eculizumab Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: 1 Indications and usage soliris: is a complement inhibitor indicated for: the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis.
- 2 Real-world patient consensus: 86% patient "Worth It" rating across 8 anonymous logs for Eculizumab (RxNorm 700384).
- 3 Typical cash cost range: Uninsured 30-day outlay compares $125.95 cash mean against $308.58 retail pharmacy pricing.
- 4 Top reported side effects / signs: Key post-marketing and trial adverse reactions (Eculizumab): nausea (11.4%), headache (10%), nasopharyngitis (8.1%).
Ask our AI Specialists anything about Eculizumab
Eculizumab Mechanism, CYP450 Pathways & DailyMed Monograph
1 Indications and usage soliris: is a complement inhibitor indicated for: the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis. ( 1.1 ) the treatment of patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy. ( 1.2 ) Limitation of Use SOLIRIS is not indicated for the treatment of patients with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS).
12.1 Mechanism of Action Eculizumab, the active ingredient in SOLIRIS, is a monoclonal antibody that specifically binds to the complement protein C5 with high affinity, thereby inhibiting its cleavage to C5a and C5b and preventing the generation of the terminal complement complex C5b-9. SOLIRIS inhibits terminal complement-mediated intravascular hemolysis in PNH patients and complement-mediated thrombotic microangiopathy (TMA) in patients with aHUS.
Clinical clearance of Eculizumab (Complement Inhibitor) relies on phase i/ii hepatic conjugation of eculizumab coupled with glomerular and tubular renal excretion with a Approximately 9–18 hours terminal plasma half-life for Eculizumab half-life; patients absorbing at Complete (~100%) parenteral systemic delivery for Eculizumab (300 mg/30mL Injection, Solution, Concentrate) bioavailability typically observe target onset around rapid intravascular/parenteral onset within 15–45 minutes after eculizumab administration.
FDA clinical labeling for Eculizumab restricts administration in 4 contraindications soliris is contraindicated for initiation in patients with unresolved serious neisseria meningitidis infection .; soliris is contraindicated for initiation in patients with unresolved serious neisseria meningitidis infection. across 300 mg/30mL Injection, Solution, Concentrate, Organ-function-adjusted Eculizumab maintenance interval, with self-reported patient tracking dominated by nausea (11.4% of reports), headache (10% of reports), nasopharyngitis (8.1% of reports).
Avoid overlapping complement inhibitor prescriptions alongside Eculizumab to prevent cumulative receptor toxicity.
Unstandardized herbal extracts may interact pharmacodynamically with Eculizumab maintenance therapy.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- 4 CONTRAINDICATIONS SOLIRIS is contraindicated for initiation in patients with unresolved serious Neisseria meningitidis infection .
- SOLIRIS is contraindicated for initiation in patients with unresolved serious Neisseria meningitidis infection.
Logged Side-Effect Incidence (8 Reports)
Eculizumab Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Eculizumab)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Eculizumab single-drug treatment for NMOSD: Data from PREVENT and its open-label Eculizumab single-drug treatment provides effective long-term relapse prevention, relieving the chronic immunosuppression burden in patients with AQP4-IgG + NMOSD.. Multiple sclerosis (Houndmills, Basingstoke, England) • 2022-03-15 • Phase III Randomized Trial | N = 33 | 88/100 | PMID 34498507 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of eculizumab in Guillain-Barré syndrome: A phase 3, Although well tolerated, eculizumab treatment did not show significant effects on motor function recovery compared to placebo in patients with GBS. Journal of the peripheral nervous system : JPNS • 2024-09-15 • Phase III Randomized Trial | N = 57 | 88/100 | PMID 38987228 ↗ |
| Can This Approach Help? Inside the Latest Research on [The real-world benefits and safety of eculizumab biosimilar in patients with The study established the equivalent efficacy of biosimilar product Acveris and referent eculizumab product with the evidence of effective suppression of intravascular hemolysis in PNH patients along with a comparable... Terapevticheskii arkhiv • 2021-11-15 • Phase III Randomized Trial | N = 14 | 82/100 | PMID 36286657 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of crovalimab versus eculizumab in complement inhibitor-naïve Over 24 weeks, 91% of patients achieved complete terminal complement inhibition with crovalimab. Annals of hematology • 2026-06-13 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 42287326 ↗ |
| Can This Approach Help? Inside the Latest Research on Normalization of Hemoglobin, Lactate Dehydrogenase, and Fatigue in Patients with PEG is superior to ECU and supportive care in hemoglobin, LDH, and FACIT-Fatigue score normalization for patients with PNH and persistent anemia despite ≥3 months of treatment with ECU, and in C5 inhibitor-naive patients. Drugs in R&D • 2024-06-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 38727860 ↗ |
Eculizumab Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $2.9000/unit (~$87.00/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $308.58 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 8 Anonymous DotMD Community Micro-Logs | $125.95 / mo | View logs ↓ |
Eculizumab Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Eculizumab RxNorm Concept ID | 700384 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $2.9000 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $308.58 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $125.95 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 86.00% Worth It (8 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Eculizumab Patient Community, Cohort Filters & Dosage Logs
Deterministic Eculizumab reference combining NIH RxNorm (700384), Medicaid NADAC ($2.9000/unit), and anonymous cohort outcomes (86% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Eculizumab community threads and patient logs by age, biological sex, dosage, and treatment duration.